A potential pharmaceutical intervention for co-occurring PTSD and substance use disorder
N-acetylcysteine reduced PTSD symptoms, cravings, and depression in veterans with PTSD and substance use disorder in a randomized controlled pilot trial conducted -
N-acetylcysteine (NAC), when combined with group cognitive behavioral therapy (CBT), reduced symptoms of post traumatic stress disorder (PTSD), cravings, and depression significantly more than CBT alone in veterans with co-occurring PTSD and substance use disorder, a particularly difficult-to-treat population, according to the findings of a randomized controlled pilot trial conducted by researchers at the Medical University of South Carolina (MUSC) and the Ralph H. Johnson VA Medical Center.
This trial is the first to use NAC as a pharmacotherapy for PTSD and a broad range of substance use disorders. The results are published by the Journal of Clinical Psychiatry.
The National Center for PTSD (U.S.) estimates that seven to eight percent of those in the U.S. will have PTSD at some point in their life. The numbers are even worse for veterans: it is estimated, for example, that 30 percent of veterans who served in Vietnam will have experienced PTSD at some point in their life. Approximately 40 to 50 percent of veterans with PTSD also have a substance use disorder.
"Addiction goes along with virtually every psychiatric disorder at a higher percentage than it does in the general population" said Peter W. Kalivas, PhD the senior author on the article and chair of the Department of Neuroscience at MUSC. "People who are prone to psychiatric disorders are also prone to addiction."
Currently, there are no well-explored pharmacological treatments for patients with co-occurring PTSD/substance use disorder. Although selective serotonin reuptake inhibitors have been approved by the U.S. Food and Drug Administration for treatment of PTSD, pharmacological treatments for co-occurring PTSD/substance use disorder have yielded suboptimal results.
Research by Kalivas has shown that levels of glutamate transporters are decreased in substance use disorders and that administration of the antioxidant N-acetylcysteine can help restore those levels and guard against relapse in animal models of substance use disorder. Because evidence suggests that substance use disorders and PTSD share overlapping neurobiological pathways, Sudie E. Back, PhD, lead author on the article, hypothesized that NAC treatment with CBT would be a novel approach to treat co-occurring PTSD and substance use disorder.
Back is a professor in the Department of Psychiatry and Behavioral Sciences at MUSC and a staff psychologist at the Ralph H. Johnson VA Medical Center.
In the eight-week randomized controlled trial led by Back and Kalivas, 35 veterans with PTSD and substance use disorder, all of whom were receiving cognitive behavioral therapy (CBT) for their substance use disorder, were randomized to either 2400 mg/day of NAC or placebo. The average age of the veterans was 49 years and many were veterans of the Vietnam War. To be included, veterans had to have abstained from substance use for at least seven days. Of the veterans enrolled in the trial, 83 percent completed it, a very high rate for this difficult-to-treat population.
Don't Miss: In pursuit of precision medicine for PTSD
Veterans in the NAC-treated group showed a 46 percent reduction in PTSD symptoms, compared with a 25 percent reduction in the placebo group on the Clinical-Administered PTSD Scale (CAPS), which assesses trauma history and symptom severity. The threshold CAPS score for diagnosis of PTSD is 50.
"As a group, the NAC-treated veterans were below diagnostic level for PTSD at the end of treatment," said Back. "For PTSD, these are some of the best outcomes we have seen in the literature for a medication."
Craving and depression were also reduced in the NAC-treated group. The amount of craving was reduced by 81 percent and the frequency of craving by 71 percent in the NAC group, compared with 32 percent and 29 percent in the placebo group. "Craving is a key component of substance use in relapse," said Back. "If you have a medication that can really reduce craving, that will go a long way to helping people stay clean and sober." Depression, gauged using the Beck Depression Inventory, was reduced 48 percent in the NAC group vs. 15 percent in the placebo group.
Veterans in the study had low rates of substance use during the trial, and the study found little effect of medication on use, perhaps due to the fact that all participants were receiving substance use disorder treatment and exhibiting low levels of use. This finding could also be due to the relatively limited number of participants or to the chronic nature of the participants' PTSD. "This is a tough patient population with substance use disorder to work with." said Kalivas. "We have Vietnam vets that have had PTSD for 15 to 20 years. This is not an easy-to-turn-around population."
Although these early, promising findings show that NAC reduced PTSD symptoms, craving, and depression, NAC should not be used as a monotherapy or substitute for evidence-based behavioral treatment, but instead be seen as an adjunct therapy that enhances it.
"We would not advocate using it instead of therapy," said Back. "But this could be something to help prevent relapse when used alongside a behavioral treatment."
NAC is available over the counter and does not cause side effects at the doses used in the study, but it degrades quickly when stored, is contraindicated in patients with asthma, and can cause nausea at higher doses and so should always be obtained and administered under a physician's supervision.
The next steps in Back's research are to run a longer-term trial of NAC in veterans with PTSD and substance use disorder and to use magnetic resonance spectroscopy to better explore the effect of NAC on glutamate levels in patients with PTSD and substance use disorder.
Note: Material may have been edited for length and content. For further information, please contact the cited source.
Back SE et al. A Double-Blind, Randomized, Controlled Pilot Trial of N-Acetylcysteine in Veterans With Posttraumatic Stress Disorder and Substance Use Disorders. Journal of Clinical Psychiatry, Published 2016. doi: 10.4088/JCP.15m10239